Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15814104rdf:typepubmed:Citationlld:pubmed
pubmed-article:15814104lifeskim:mentionsumls-concept:C0031330lld:lifeskim
pubmed-article:15814104lifeskim:mentionsumls-concept:C0034830lld:lifeskim
pubmed-article:15814104lifeskim:mentionsumls-concept:C0486616lld:lifeskim
pubmed-article:15814104lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:15814104lifeskim:mentionsumls-concept:C1510438lld:lifeskim
pubmed-article:15814104lifeskim:mentionsumls-concept:C0679622lld:lifeskim
pubmed-article:15814104lifeskim:mentionsumls-concept:C0205314lld:lifeskim
pubmed-article:15814104lifeskim:mentionsumls-concept:C1711351lld:lifeskim
pubmed-article:15814104lifeskim:mentionsumls-concept:C0752283lld:lifeskim
pubmed-article:15814104pubmed:issue5lld:pubmed
pubmed-article:15814104pubmed:dateCreated2005-4-7lld:pubmed
pubmed-article:15814104pubmed:abstractTextThe subunit composition and pharmacology of alpha-Conotoxin MII-binding (alpha-CtxMII) nicotinic acetylcholine receptors (nAChR) was studied by an improved [(125)I]-alpha-CtxMII membrane binding method. This binding method facilitates pharmacological studies that have been difficult to accomplish with [(125)I]-alpha-CtxMII autoradiography or alpha-CtxMII inhibition of [(125)I]-epibatidine binding. Binding densities and K(d)-values obtained by this [(125)I]-alpha-CtxMII membrane binding were similar to the values obtained by autoradiography or alpha-CtxMII inhibition of [(125)I]-epibatidine binding, verifying that each of these approaches measures the same nAChR population. Binding results with nAChR subunit-null mutant mice confirm and extend observations from earlier studies: [(125)I]-alpha-CtxMII binding measures two sets of alpha6beta2* nAChR (alpha4alpha6beta2beta3 or alpha6beta2beta3). Most nicotinic agonists and antagonists show monophasic inhibition of [(125)I]-alpha-CtxMII binding, indicating that alpha4alpha6beta2beta3 and alpha6beta2beta3 have similar binding properties. Comparison of the binding and activation profiles of alpha6beta2* nAChR to those of other nAChR subtypes (alpha4beta2* and beta4*) indicates that these receptors have distinctly different pharmacology indicating that it may be possible to target alpha6beta2* nAChR selectively to develop compounds that might be therapeutically useful.lld:pubmed
pubmed-article:15814104pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15814104pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15814104pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15814104pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15814104pubmed:languageenglld:pubmed
pubmed-article:15814104pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15814104pubmed:citationSubsetIMlld:pubmed
pubmed-article:15814104pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15814104pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15814104pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15814104pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15814104pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15814104pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15814104pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15814104pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15814104pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15814104pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15814104pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15814104pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15814104pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15814104pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15814104pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15814104pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15814104pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15814104pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15814104pubmed:statusMEDLINElld:pubmed
pubmed-article:15814104pubmed:monthAprlld:pubmed
pubmed-article:15814104pubmed:issn0028-3908lld:pubmed
pubmed-article:15814104pubmed:authorpubmed-author:McIntoshJ...lld:pubmed
pubmed-article:15814104pubmed:authorpubmed-author:CollinsAllan...lld:pubmed
pubmed-article:15814104pubmed:authorpubmed-author:MarksMichael...lld:pubmed
pubmed-article:15814104pubmed:authorpubmed-author:WhiteakerPaul...lld:pubmed
pubmed-article:15814104pubmed:authorpubmed-author:GradySharon...lld:pubmed
pubmed-article:15814104pubmed:authorpubmed-author:SalminenOutiOlld:pubmed
pubmed-article:15814104pubmed:issnTypePrintlld:pubmed
pubmed-article:15814104pubmed:volume48lld:pubmed
pubmed-article:15814104pubmed:ownerNLMlld:pubmed
pubmed-article:15814104pubmed:authorsCompleteYlld:pubmed
pubmed-article:15814104pubmed:pagination696-705lld:pubmed
pubmed-article:15814104pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:15814104pubmed:meshHeadingpubmed-meshheading:15814104...lld:pubmed
pubmed-article:15814104pubmed:meshHeadingpubmed-meshheading:15814104...lld:pubmed
pubmed-article:15814104pubmed:meshHeadingpubmed-meshheading:15814104...lld:pubmed
pubmed-article:15814104pubmed:meshHeadingpubmed-meshheading:15814104...lld:pubmed
pubmed-article:15814104pubmed:meshHeadingpubmed-meshheading:15814104...lld:pubmed
pubmed-article:15814104pubmed:meshHeadingpubmed-meshheading:15814104...lld:pubmed
pubmed-article:15814104pubmed:meshHeadingpubmed-meshheading:15814104...lld:pubmed
pubmed-article:15814104pubmed:meshHeadingpubmed-meshheading:15814104...lld:pubmed
pubmed-article:15814104pubmed:meshHeadingpubmed-meshheading:15814104...lld:pubmed
pubmed-article:15814104pubmed:meshHeadingpubmed-meshheading:15814104...lld:pubmed
pubmed-article:15814104pubmed:meshHeadingpubmed-meshheading:15814104...lld:pubmed
pubmed-article:15814104pubmed:meshHeadingpubmed-meshheading:15814104...lld:pubmed
pubmed-article:15814104pubmed:meshHeadingpubmed-meshheading:15814104...lld:pubmed
pubmed-article:15814104pubmed:meshHeadingpubmed-meshheading:15814104...lld:pubmed
pubmed-article:15814104pubmed:meshHeadingpubmed-meshheading:15814104...lld:pubmed
pubmed-article:15814104pubmed:meshHeadingpubmed-meshheading:15814104...lld:pubmed
pubmed-article:15814104pubmed:meshHeadingpubmed-meshheading:15814104...lld:pubmed
pubmed-article:15814104pubmed:meshHeadingpubmed-meshheading:15814104...lld:pubmed
pubmed-article:15814104pubmed:meshHeadingpubmed-meshheading:15814104...lld:pubmed
pubmed-article:15814104pubmed:meshHeadingpubmed-meshheading:15814104...lld:pubmed
pubmed-article:15814104pubmed:meshHeadingpubmed-meshheading:15814104...lld:pubmed
pubmed-article:15814104pubmed:meshHeadingpubmed-meshheading:15814104...lld:pubmed
pubmed-article:15814104pubmed:meshHeadingpubmed-meshheading:15814104...lld:pubmed
pubmed-article:15814104pubmed:meshHeadingpubmed-meshheading:15814104...lld:pubmed
pubmed-article:15814104pubmed:meshHeadingpubmed-meshheading:15814104...lld:pubmed
pubmed-article:15814104pubmed:meshHeadingpubmed-meshheading:15814104...lld:pubmed
pubmed-article:15814104pubmed:meshHeadingpubmed-meshheading:15814104...lld:pubmed
pubmed-article:15814104pubmed:meshHeadingpubmed-meshheading:15814104...lld:pubmed
pubmed-article:15814104pubmed:year2005lld:pubmed
pubmed-article:15814104pubmed:articleTitleThe subunit composition and pharmacology of alpha-Conotoxin MII-binding nicotinic acetylcholine receptors studied by a novel membrane-binding assay.lld:pubmed
pubmed-article:15814104pubmed:affiliationInstitute for Behavioral Genetics, University of Colorado, Boulder, 80309, USA. outi.salminen@helsinki.filld:pubmed
pubmed-article:15814104pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15814104pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:15814104pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:15814104pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:15814104pubmed:publicationTypeResearch Support, N.I.H., Extramurallld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15814104lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15814104lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15814104lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15814104lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15814104lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15814104lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15814104lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15814104lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15814104lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15814104lld:pubmed